From: Progress in oncolytic virotherapy for the treatment of thyroid malignant neoplasm
Virus | Genome | Genetic alterations | Delivery | Combination | Phase | References |
---|---|---|---|---|---|---|
Adenovirus | dsDNA | P53 (rAD-p53) | IT | Radioactive iodine/ Surgery | IV | 24 |
 |  | P53 (ONYX-015) | IT | Cisplatin/5-fluorouracil | Marketed | 27 |
 |  | Fas-c (VB-111) | IV | Anti-angiogenic agent | II | 29 |
Reovirus | dsRNA | Natural strain (RT3D) | IT | Low-dose radiation/ | II | 35 |
 |  |  | IT/IV | Gemcitabine/Carboplatin/Paclitaxel/Docetaxel | III | 37. 38 |
Herpes simplex virus | dsDNA | N/A | Â | Â | Â | Â |
Vaccina virus | dsDNA | N/A | Â | Â | Â | Â |
New castle disease virus | ssRNA | N/A | Â | Â | Â | Â |
Vesicular virus | ssRNA | N/A | Â | Â | Â | Â |
Measles virus | ssRNA | N/A | Â | Â | Â | Â |
Retrovirus | ssRNA | N/A | Â | Â | Â | Â |